Nivolumab
Infiltrating Bladder Urothelial Carcinoma
Explore 15 assets in Infiltrating Bladder Urothelial Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05987241CT.gov Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | — | Recruiting | — | — | — |
NCT03866382CT.gov Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Infiltrating Bladder Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | National Cancer Institute (NCI) | P2/3 | B · 62 |
| Pembrolizumab | Fred Hutchinson Cancer Center | P2/3 | B |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2/3 | B |
| Cis-Diamminedichloroplatinum Ii | Vasgene Therapeutics, Inc | P2/3 | B |
| Relatlimab | National Cancer Institute (NCI) | P2/3 | B |
| Recombinant Ephb4-Hsa Fusion Protein | Vasgene Therapeutics, Inc | P2/3 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Rucaparib | pharmaand GmbH | P2 | CCC |
| Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 | National Cancer Institute (NCI) | P2 | CCC |
+7 more in the Infiltrating Bladder Urothelial Carcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PembrolizumabFred Hutchinson Cancer CenterB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterB
- Cis-Diamminedichloroplatinum IiVasgene Therapeutics, IncB
- RelatlimabNational Cancer Institute (NCI)B
- Recombinant Ephb4-Hsa Fusion ProteinVasgene Therapeutics, IncCCC
Citation
Floatz Terminal. Nivolumab in Infiltrating Bladder Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-infiltrating-bladder-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →